NCT04884009

A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer

An Open-label, Multicenter PhaseⅡ Study of SHR-1701 in Combination With or Without Famitinib Malate for the Treatment of Extensive Stage Small Cell Lung Cancer After Previous Systemic Chemotherapy Failure

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 106 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The study is being conducted to evaluate the efficacy and safety of SHR-1701 in combination with or without famitinib malate for the treatment of extensive stage small cell lung cancer after the failure of previous systemic chemotherapy

Conditions

• Lung Cancer

Interventions

Type	Name	Description
DRUG	SHR-1701； Famitinib	SHR-1701+ Famitinib
DRUG	SHR-1701	SHR-1701

Timeline

• Start date: 2021-05-31
• Primary completion: 2022-12-31
• Completion: 2022-12-31
• First posted: 2021-05-12
• Last updated: 2021-05-12